Reviva Pharmaceuticals Holdings, Inc. financial data

Symbol
RVPH, RVPHW on Nasdaq
Industry
Pharmaceutical Preparations
Location
10080 N Wolfe Road, Suite Sw3 200, Cupertino, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Tenzing Acquisition Corp. (to 12/14/2020)
Latest financial report
10-K - Q4 2024 - Apr 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -370 % +55.9%
Return On Assets -268 % +8.19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.7M shares +67.4%
Common Stock, Shares, Outstanding 46.6M shares +66.8%
Entity Public Float 31.8M USD
Common Stock, Value, Issued 4.66K USD +66.8%
Weighted Average Number of Shares Outstanding, Basic 33.1M shares +39.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.9M USD -27.1%
General and Administrative Expense 7.89M USD -2.38%
Operating Income (Loss) -30.8M USD +22%
Nonoperating Income (Expense) 900K USD +246%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29.9M USD +23.8%
Income Tax Expense (Benefit) 19.5K USD +15.1%
Net Income (Loss) Attributable to Parent -29.9M USD +23.8%
Earnings Per Share, Basic -0.9 USD/shares +45.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.5M USD -42.3%
Assets, Current 14.7M USD -38%
Assets 15.5M USD -34.6%
Accounts Payable, Current 6.28M USD +63.2%
Employee-related Liabilities, Current 636K USD -33.7%
Liabilities, Current 14.6M USD -15%
Liabilities 14.7M USD -18.3%
Retained Earnings (Accumulated Deficit) -164M USD -22.3%
Stockholders' Equity Attributable to Parent 813K USD -85.8%
Liabilities and Equity 15.5M USD -34.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.7M USD -47.5%
Net Cash Provided by (Used in) Financing Activities 332K USD -51.7%
Common Stock, Shares Authorized 315M shares 0%
Common Stock, Shares, Issued 46.6M shares +66.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.49K USD
Deferred Tax Assets, Valuation Allowance 31.5M USD +14.5%
Deferred Tax Assets, Gross 31.5M USD +14.5%
Depreciation 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 15.7M USD +2.77%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.7M USD +112%
Additional Paid in Capital 165M USD +17.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.63M USD -52.2%
Interest Expense 3.49K USD -54.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%